Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A California cancer consortium phase II trial

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 442-447

  Lau, D ^a   Leigh, B ^a   Gandara, D ^a   Edelman, M ^a   Morgan, R ^a   Israel, V ^a   Lara, P ^a   Wilder, R ^a   Ryu, J ^a   Doroshow, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0035863292     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.442     Document Type: Article

References (18)

1. Taxol: A novel radiation sensitizer
2. Paclitaxel as a radiation sensitizer in non-small-cell lung cancer
3. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
4. Promotion of microtubule assembly in vitro by Taxol
5. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer
6. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
7. Phase I/II trial of combination carboplatin and taxol in non-small cell lung cancer
8. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
9. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
10. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): Three year follow-up
11. Optimal two-stage designs for phase II clinical trials
12. Nonparametric estimation from incomplete observations
13. Chemoradiation for locally advanced, unresectable NSCLC
14. Integration of new chemotherapeutic agents into multimodality therapy for non-small-cell lung cancer
15. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer
16. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer
17. Premedication strategy for weekly paclitaxel based on experience with 1,608 infusions of 3- and 4-week paclitaxel
18. Preliminary analysis of a phase II study of paclitaxel, carboplatin and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer